Journey Medical Corporation (DERM)Healthcare | Drug Manufacturers - Specialty & Generic | Scottsdale, United States | NasdaqCM
6.86 USD
-0.05
(-0.724%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 6.86 |
Hot Take ↕ | July 11, 2026, 6:15 a.m. EDT
The investment case here is a study in contrasts between a recovering business and a broken capital structure. Fundamentally, the company has turned the corner: revenue grew 21.5%, gross margins expanded to 65%, and the stock has rallied 100% over the last three years, ending on a positive annual note. This turnaround justifies a 'slightly positive' long-term lean, though the negative operating cash flow and loss-making status prevent a top-tier rating. However, the short-term outlook is clouded by severe liquidity risks. The stock trades at a premium to book value despite negative earnings, and the balance sheet shows a precarious debt-to-equity ratio of 82.6%. More critically, the company faces 'going concern' risks mentioned in recent headlines, which casts a shadow over any near-term price appreciation. The statistical forecast model offers no directional bias, and the options market is virtually silent, reflecting a lack of conviction among traders. Until the balance sheet stabilizes and the going concern risks are resolved, the stock remains a speculative hold rather than a clear trade. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.174657 |
| AutoETS | 0.185206 |
| AutoTheta | 0.185210 |
| AutoARIMA | 0.185918 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 3.90 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.131 |
| Excess Kurtosis | 0.18 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 82.602 |
| Revenue per Share | 2.52 |
| Market Cap | 188,887,008 |
| Forward P/E | -114.33 |
| Beta | 1.07 |
| Profit Margins | -14.82% |
| Website | https://journeymedicalcorp.com |
As of July 11, 2026, 6:15 a.m. EDT: Options activity is extremely thin with negligible open interest and volume across all expirations. Implied volatility is near zero for longer-dated contracts, indicating a lack of speculative positioning or hedging. The sparse data suggests the market is largely ignoring this instrument for directional bets.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.06747639 |
| Address1 | 9,237 East Via de Ventura Blvd. |
| Address2 | Suite 105 |
| All Time High | 10.2 |
| All Time Low | 1.02 |
| Ask | 8.72 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 397,500 |
| Average Daily Volume3 Month | 273,154 |
| Average Volume | 273,154 |
| Average Volume10Days | 397,500 |
| Beta | 1.073 |
| Bid | 4.95 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 1.128 |
| City | Scottsdale |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 6.86 |
| Current Ratio | 1.717 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 6.95 |
| Day Low | 6.72 |
| Debt To Equity | 82.602 |
| Earnings Call Timestamp End | 1,778,704,200 |
| Earnings Call Timestamp Start | 1,778,704,200 |
| Earnings Timestamp | 1,778,702,400 |
| Earnings Timestamp End | 1,786,478,400 |
| Earnings Timestamp Start | 1,786,478,400 |
| Ebitda | -2,021,000 |
| Ebitda Margins | -0.03125 |
| Enterprise To Ebitda | -92.595 |
| Enterprise To Revenue | 2.893 |
| Enterprise Value | 187,134,992 |
| Eps Forward | -0.06 |
| Eps Trailing Twelve Months | -0.37 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.1069 |
| Fifty Day Average Change | 0.7530999 |
| Fifty Day Average Change Percent | 0.12331951 |
| Fifty Two Week Change Percent | -6.747639 |
| Fifty Two Week High | 9.555 |
| Fifty Two Week High Change | -2.6950002 |
| Fifty Two Week High Change Percent | -0.2820513 |
| Fifty Two Week Low | 4.31 |
| Fifty Two Week Low Change | 2.5500002 |
| Fifty Two Week Low Change Percent | 0.5916474 |
| Fifty Two Week Range | 4.31 - 9.555 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,636,727,400,000 |
| Float Shares | 14,903,074 |
| Forward Eps | -0.06 |
| Forward P E | -114.333336 |
| Free Cashflow | -3,300,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 58 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.65442 |
| Gross Profits | 42,328,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.32770002 |
| Held Percent Institutions | 0.59177 |
| Implied Shares Outstanding | 27,534,547 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,021-11-12 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. |
| Long Name | Journey Medical Corporation |
| Market | us_market |
| Market Cap | 188,887,008 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_280596341 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -9,588,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 190,401,392 |
| Number Of Analyst Opinions | 4 |
| Open | 7.07 |
| Operating Cashflow | -6,700,000 |
| Operating Margins | -0.09348 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 480 434 6670 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 6.86 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 6.91 |
| Price Hint | 2 |
| Price To Book | 6.08156 |
| Price To Sales Trailing12 Months | 2.920331 |
| Profit Margins | -0.14824 |
| Quick Ratio | 1.38 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0499997 |
| Regular Market Change Percent | -0.723585 |
| Regular Market Day High | 6.95 |
| Regular Market Day Low | 6.72 |
| Regular Market Day Range | 6.72 - 6.95 |
| Regular Market Open | 7.07 |
| Regular Market Previous Close | 6.91 |
| Regular Market Price | 6.86 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 157,654 |
| Return On Assets | -0.044899996 |
| Return On Equity | -0.36615002 |
| Revenue Growth | 0.215 |
| Revenue Per Share | 2.52 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 21,534,547 |
| Shares Percent Shares Out | 0.1086 |
| Shares Short | 2,990,671 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,514,547 |
| Short Name | Journey Medical Corporation |
| Short Percent Of Float | 0.1973 |
| Short Ratio | 8.26 |
| Source Interval | 15 |
| State | AZ |
| Symbol | DERM |
| Target High Price | 16.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 13.5 |
| Target Median Price | 13.0 |
| Total Cash | 27,219,000 |
| Total Cash Per Share | 0.989 |
| Total Debt | 25,467,000 |
| Total Revenue | 64,680,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.37 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.104675 |
| Two Hundred Day Average Change | -0.24467468 |
| Two Hundred Day Average Change Percent | -0.034438547 |
| Type Disp | Equity |
| Volume | 157,654 |
| Website | https://journeymedicalcorp.com |
| Zip | 85,258 |